Almost every obesity trial answers the same question: how much weight comes off while the drug is being given. Far fewer ask what happens next. SURMOUNT-MAINTAIN, published in The Lancet on 6 June 2026, was designed around that second question — and its design is what makes it worth reading carefully.
This was a phase 3b, placebo-controlled trial running 112 weeks across 20 sites in the United States, in two distinct phases:
Enrolment required a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity, plus a history of at least one unsuccessful dietary attempt. 441 participants entered the weight-loss period; 378 were randomised at week 60 — 140 to MTD, 144 to 5 mg, 94 to placebo. 345 of the 378 (91%) completed the study. Mean age was 46.6 years, mean baseline bodyweight 113.8 kg, mean BMI 40.1 kg/m².
| Arm (weeks 60–112) | Bodyweight change from baseline | Needed rescue therapy |
|---|---|---|
| Continued at MTD | −21.9% (95% CI −23.5 to −20.3) | 11 of 138 (8%) |
| Reduced to 5 mg | −16.6% (95% CI −18.0 to −15.1) | 35 of 142 (25%) |
| Switched to placebo | −9.9% (95% CI −11.1 to −8.8) | 60 of 90 (67%) |
All three between-arm comparisons reached p<0.0001. "Rescue therapy" means the participant regained more than 50% of the weight they had lost and was given tirzepatide again — available from week 84 onward.
The headline percentages are the ones that get quoted, but the rescue-therapy column is arguably more informative. Two thirds of the placebo arm regained more than half of what they had lost, against 8% of those who stayed on the maximum tolerated dose. That is not a subtle gradient — it is the difference between a maintained result and a reverting one.
The 5 mg arm sits in between, and deliberately so. The trial was not only asking "continue or stop"; it was asking whether a reduced dose is a real third option. At 25% rescue and −16.6% maintained, it landed closer to continuation than to withdrawal, which is the finding the authors highlight as clinically useful.
Tirzepatide is a dual agonist: it engages both the GLP-1 and the GIP receptor. Comparisons between compounds — semaglutide against tirzepatide, or either against the investigational triple agonist retatrutide — are almost always framed around peak weight reduction during active treatment. SURMOUNT-MAINTAIN is a reminder that peak reduction and durability are separate measurements, and that a trial reporting one says nothing automatic about the other.
For anyone reading incretin literature, the practical lesson is to check which phase a reported number comes from. A figure from an open-label loss period and a figure from a blinded maintenance period are not interchangeable, even when both appear in the same publication.
Universe Peptide supplies Tirzepatide for in-vitro laboratory research, with a third-party Certificate of Analysis (COA) available for each lot:
Browse GLP research compounds →